We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioInvent Recruits Michael Oredsson as New CEO
News

BioInvent Recruits Michael Oredsson as New CEO

BioInvent Recruits Michael Oredsson as New CEO
News

BioInvent Recruits Michael Oredsson as New CEO

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioInvent Recruits Michael Oredsson as New CEO"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioInvent International AB has announced that the Company's Board of Directors has appointed Michael Oredsson as new President and CEO.

Michael Oredsson has a degree in International Business Administration and has for many years held senior executive positions in the pharmaceutical and biotech industry.

He is currently the CEO of Probi AB and has held his earlier executive positions at, among others, Pharmacia Corporation.

BioInvent’s chairman Björn O. Nilsson says in a comment "We are very pleased to have been able to recruit a new CEO with a broad and international experience from different parts of the life science industry. We are confident that Michael's expertise and experience of licenses, contracts and commercial solutions and collaborations will be of great importance for our new strategic direction, which include increased focus on developing existing and new alliances with partners based on our technology platform and project portfolio."

"BioInvent is a very interesting company with broad knowledge, strong technologies and numerous partnerships in the field of antibody therapeutics. The company's new strategy provides exciting opportunities and I look forward to leading this work, "says Michael Oredsson.

Advertisement